Voss Technology, which aims to build an AI decision-making platform for pharmaceutical industry scenarios, recently announced the completion of 10 million yuan angel round financing, with linear capital as the investor, and shareholders will continue to make additional investments in the last round.
Voss Technology said that the next step will be to build an AI automated synthesis platform, combining the use of hardware integration and software fine control to achieve breakthroughs in the field of synthesis automation, thereby empowering R&D personnel to play an advantage in more creative fields. At present, we have talked with our customers about cooperation, and it is expected that a prototype will be launched next year.
"Deep Genomics" completed the C round of financing of 65.438 USD +0.8 billion.
Recently, Deep Genomics, an artificial intelligence-driven RNA therapy development company, announced the completion of the C-round financing of $654.38+RMB 800 million. The funds obtained will be used to promote the construction of deep genome AI platform and the development of RNA therapy pipeline.
Deep Genomics has established a system called AI Workbench, which has predicted the entire human genome, millions of genetic variations and hundreds of millions of new compounds for billions of times. At present, AI Workbench has been iterated to version 3.0, which supports target recognition and drug discovery of more common and complex diseases, covering neurodevelopmental, neurodegenerative and metabolic diseases.
"T-knife": Let TCR-T cell therapy go to clinic.
Recently, T- Knife Therapeutics raised $ 1. 1 billion in the second round of financing to develop the next generation of fully personalized neonatal antigen T cell receptor (TCR) therapy.
Through the pioneering work of its co-founder, Professor Thomas Blankenstein, T-knife established its own HuTCR transgenic mouse platform carrying the whole human TCRαβ gene locus, which only expressed human TCR limited to human HLA. At the same time, related studies also show that the anti-tumor activity of TCR CD4+ and CD8+T cells with optimized affinity/specificity can be significantly improved by immunizing HuTCR mice with human tumor antigen. T-knife established a very diverse TCR library through effective gene initiation and TCR selection in the follow-up work. Using this natural high affinity TCR selection platform, a series of TCR candidate drugs with unique patents were developed for clinical use.
"Zhonghui Tong Yuan" received a Pre-IPO round of financing of over 600 million yuan.
Zhonghuiyuantong received Pre-IPO financing of more than 600 million yuan, with investors including Yingke Capital, Honghui Capital, Guohai Innovation Capital and Songhe Capital.
Zhonghui Tong Yuan is a professional company engaged in vaccine research and development, registration, industrialization and sales. At present, the company has obtained four clinical approvals for the first-class new drugs, namely tetravalent influenza virus subunit vaccine for children, tetravalent influenza virus subunit vaccine for adults, recombinant herpes zoster vaccine and nonavalent recombinant human papillomavirus vaccine, and nine new drugs 1 clinical approval for the trivalent pneumococcal polysaccharide vaccine.
Jindike Bio is listed on the Science and Technology Innovation Board of Shanghai Stock Exchange.
On August 2nd, Kindike Bio was officially listed on the Science and Technology Innovation Board of Shanghai Stock Exchange. According to the prospectus of Kindike Bio, the sponsor of this IPO is CITIC Securities, with an issue price of RMB 5,565,438+08 per share, and the total amount of funds raised is about RMB 6,543.806 billion. Kindike Bio was established in 2008 and has been focusing on the research, development, production and sales of vaccines for human use.
Dong Bo Medicine focuses on vascular interventional diagnosis and treatment.
Broadcom Medical Imaging Technology (Shanghai) Co., Ltd. (Broadcom Medical) announced the completion of the C-round financing of over 1 billion USD. This round of financing funds will be used to accelerate the company's product commercialization, new product research and development, clinical registration, and further improve the global layout of vascular interventional diagnosis and treatment.
Dong Bo Pharmaceutical was established in September 20 15. By the industry's top management team and the world's top scientists, we are committed to becoming the global leader in vascular interventional diagnosis and treatment. The company's products cover the complete industrial chain of vascular interventional diagnosis and treatment, such as accurate screening of vascular diseases, intraoperative diagnosis and surgical planning, postoperative efficacy evaluation and patient risk prediction. Up to now, Broadcom Medical has more than 70 patents in China, the United States, Germany and Japan, and has a number of world-first top technologies.
"Enze Kangtai" foreign body+medical service
Recently, Beijing Enze Kangtai Biotechnology Co., Ltd. (Enze Kangtai) announced the completion of nearly 100 million A round of financing. The financing proceeds will be mainly used for the construction of the company's pilot workshop for exocrine therapy, the research and development of preclinical series products and the construction of the exocrine engineering transformation technology platform.
Enze Kangtai, founded on 20 17, is the first innovative high-tech enterprise in China devoted to the research and development of exosomes and clinical transformation. Its business segments are mainly divided into: first, innovative drug research and development based on foreign bodies, mainly covering tumor immunity, rare diseases and nervous system diseases; Secondly, translational medicine research services based on foreign bodies mainly cooperate with clinical experts to carry out scientific research. At present, the business has covered major cities in China, and established cooperation with more than 50 well-known top three hospitals, scientific research units and a number of precision medical enterprises in China.
"Xingyi Ang Bio" develops NK new technology platform and products.
Recently, Nukio Biotechnology Co., Ltd. announced the completion of $40 million angel round financing. This round of funds will be mainly used for the construction of R&D facilities and the early development of universal dot immune cell technology platform and products.
Dr. Wang Liqun, founder, chairman and CEO of Xingyiang, has rich experience in biopharmaceutical technology and R&D management in the United States and China. He is the founding president of Fosun Kate, a joint venture between Fosun Pharma and Kate USA. Dr. Wang Liqun said, "Xing Yi 'ang started from Shanghai No.1 Life Science Park and is now building a core team. He is confident that he will make 0 to 1 innovation in the field of universal cell therapy. The company's angel round financing has won the favor of many famous innovative drug investment institutions. We are very grateful to Lilly Asia Fund, IDG Capital and Sherpa Investment for their recognition and support of our core team capabilities and technological innovation concepts. 」
Leader of organ chip of "Big Oak Technology"
Beijing Daxie Technology Co., Ltd. (Daxie Technology) recently announced that it has received tens of millions of A+ round financing support. Big Oak Technology is known as the pioneer in the field of organic chips on chip in China. CEO Yu Zhou revealed that this financing will not only be used to speed up the industrial chain layout of organ chips, but also be devoted to promoting the iteration of organ-like chip technology, providing highly bionic and Qualcomm-capable models for innovative drug research and development in the fields of cancer, neurodegenerative diseases and inflammatory diseases, improving the standardized culture system of organ-like chips and its application in the field of personalized precision medicine.
"Ring" focuses on gene therapy.
Recently, Ring Therapeutics has completed the Series B financing of $65,438+0./kloc-0. 70 billion, and will face various challenges in the field of gene therapy by introducing a brand-new gene therapy carrier platform.
Ring used virus groups to create Anellovectors, an engineering vector composed of single-stranded DNA loops. Once used, it will remain in the nucleus as an appendage. These engineered ring virus vectors can transfer DNA into new cells without damaging healthy tissues or activating patients' immune systems. Therefore, if patients with immune disorder or relapse need to be given drugs again, patients can also take drugs repeatedly, and there is no defect of one-time administration.
Since the establishment of 20 17, Huanhuan has been studying which viruses will not cause disease, so as to determine which viruses exist in humans and between humans. The company has found thousands of candidate vectors based on cyclic virus, which may realize gene therapy and nucleic acid drugs in various diseases. The 65,438+65,438+07 million Series B financing will help Ring expand its carrier platform, continue to build its manufacturing capacity, and provide funds for a research, so that the company can enter the clinic as soon as possible.